Search

everythinglearnresearchcommunity

for

Search:↓

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.

Paxillin may help manage androgen-related disorders like PCOS by stabilizing androgen receptor proteins.

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

Enhanced stem cells can reduce fat buildup in eye tissue for Graves' disease.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

SARMs show promise but need more evidence to prove they're better than traditional androgens.

Targeting the p300/AR axis may help treat polycystic ovary syndrome.

PTHrP and its receptor can control blood vessel growth and hair development in mouse skin.

Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.

PP405 shows promise as a new, effective treatment for hair loss with minimal side effects.

GLP-1RAs may cause hair loss but could also help regrow hair in some cases.

TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.

Carbamates may help treat androgen-dependent conditions by changing how certain lipid enzymes are produced.

A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Allopregnanolone may enhance alcohol's effects on dopamine neurons, influencing addiction risk.

Upadacitinib effectively treats pyoderma gangrenosum.

Activating androgen receptors in muscle can increase muscle mass and reduce fat.

Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.

Increased PPARGC1α relates to hair thinning in common baldness.

Triphenylphosphine oxide can increase oil production and reduce inflammation in skin cells without affecting TRPM5.